Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.45 |
| ▸ | NQO2 | P16083 | 11/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960309 | 0.99 | MTNR1A (0.46) | MTNR1ANQO2MTNR1BACHE | |
| Hydrochloric Acid SCHEMBL1644618 | 0.89 | ACHE (0.41) | MTNR1ANQO2MTNR1BACHE | |
| Hydrochloric Acid SCHEMBL1644551 | 0.88 | MTNR1A (0.45) | MTNR1ANQO2MTNR1BACHE | |
| SCHEMBL2947131 | 0.87 | MTNR1A (0.41) | MTNR1ANQO2MTNR1BACHE | |
| SCHEMBL5960384 | 0.86 | MTNR1A (0.45) | MTNR1ANQO2MTNR1BACHE | |
| Hydrochloric Acid SCHEMBL6377152 | 0.85 | MTNR1A (0.49) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7037093 | 0.84 | MTNR1A (0.50) | MTNR1ANQO2MTNR1B | |
| Fadolmidine SCHEMBL2641142 | 0.79 | ESR1 (0.58) | MTNR1ANQO2MTNR1B | |
| Fadolmidine SCHEMBL29489898 | 0.79 | ESR1 (0.58) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7110314 | 0.79 | SIGMAR1 (0.52) | MTNR1ANQO2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4667042-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-20060178417-A1 | Imidazol derivatives having affinity for alpha 2 receptors activity | SOCIETAL CDMO, INC. | 2006-08-10 | — | — | US | claimed |
| EP-1572198-B1 | NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY | ORION CORP (FI) | 2006-04-19 | — | — | EP | claimed |
| JP-2006509780-A | — | — | 2006-03-23 | — | — | JP | claimed |
| EP-1572198-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2005-09-14 | — | — | EP | claimed |
| WO-2004050635-A2 | IMIDAZOL DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 2004-06-17 | — | — | WO | claimed |
| US-7759496-B2 | 4-[6(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]1H-imidazole, an alpha 2 adrenergic agonist, for the treatment of hypertension, glaucoma, headaches, diarrhea, ischemia, drug abuse and dependence, hypotension, shock, congestive heart failure, anxiety, as decongestants, analgesics or as sedatives | ORION CORPORATION (FI) | 2010-07-20 | — | — | US | disclosed |
| US-20060178417-A1 | Imidazol derivatives having affinity for alpha 2 receptors activity | SOCIETAL CDMO, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1572198-B1 | NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY | ORION CORP (FI) | 2006-04-19 | — | — | EP | disclosed |
| EP-1572198-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004050635-A2 | IMIDAZOL DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178417-A1 | Imidazol derivatives having affinity for alpha 2 receptors activity | ADRA2A, IGF2R, ADRB2 | ACHE 3361/4885MTNR1A 328/4885NQO2 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.